# Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors

> **NCT06391918** · PHASE1 · TERMINATED · sponsor: **GenVivo, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **BIOLOGICAL:** GEN2 + Valganciclovir

## Key facts

- **NCT ID:** NCT06391918
- **Lead sponsor:** GenVivo, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-03-04
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** Sponsor strategic business decision
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06391918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06391918, "Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06391918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*